AC
PMCB icon

Ayrton Capital’s PharmaCyte Biotech PMCB Stock Holding History

Ayrton Capital’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$193K Sell
92,087
-184,905
-67% -$471K 1.31% 12
2023
Q2 		$792K Sell
276,992
-753,538
-73% -$2.26M 4.95% 7
2023
Q1 		$3M Sell
1,030,530
-2,600
-0.3% -$7.64K 10.77% 2
2022
Q4 		$3.03M Hold
1,033,130
– – 8.27% 2
2022
Q3 		$2.48M Buy
1,033,130
+880,000
+575% +$2.23M 4.35% 5
2022
Q2 		$343K Hold
153,130
– – 0.56% 43
2022
Q1 		$352K Hold
153,130
– – 0.46% 53
2021
Q4 		$383K Buy
+153,130
New +$422K 0.36% 59

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $187M AUM 179.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ayrton Capital's PMCB Position: Q3 2023 in Review

Ayrton Capital reduced its PharmaCyte Biotech (PMCB) stake by 67% in Q3 2023, selling an estimated $471K and leaving 92,087 shares worth $193K. The position accounts for 1.31% of the portfolio, ranked #12.

Ayrton Capital first reported a position in PMCB in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.03M in Q4 2022. 31 funds tracked by Wall St. Rank hold PMCB as of Q3 2023.

  • Ayrton Capital held 92,087 shares of PharmaCyte Biotech worth $193K as of Q3 2023.
  • Ayrton Capital sold 184,905 PharmaCyte Biotech shares in Q3 2023, an estimated $471K.
  • PharmaCyte Biotech made up 1.31% of Ayrton Capital's portfolio in Q3 2023, its #12 holding.
  • Ayrton Capital first reported a position in PharmaCyte Biotech in Q4 2021 and has held it in 8 quarters since.
  • Ayrton Capital's PharmaCyte Biotech position peaked at $3.03M in Q4 2022.
  • 31 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2023.

Based on Ayrton Capital's 13F filing for Q3 2023, filed 13 Nov 2023.